Elexacaftor/tezacaftor/ivacaftor as rescue therapy in a patient with the cystic fibrosis genotype F508DEL/G1244E
© 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd..
Elexacaftor/tezacaftor/ivacaftor (ETI) is a cystic fibrosis (CF) transmembrane regulator (CFTR) modulator. It is known to be efficacious in stable patients with severe pneumopathy, but there are few data concerning its effectiveness during acute exacerbations. We here describe its use in a woman with CF and respiratory failure.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Clinical case reports - 9(2021), 8 vom: 31. Aug., Seite e04713 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Salvatore, Donatello [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 03.04.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/ccr3.4713 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM330089153 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM330089153 | ||
| 003 | DE-627 | ||
| 005 | 20240403233238.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ccr3.4713 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1362.xml |
| 035 | |a (DE-627)NLM330089153 | ||
| 035 | |a (NLM)34466263 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Salvatore, Donatello |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Elexacaftor/tezacaftor/ivacaftor as rescue therapy in a patient with the cystic fibrosis genotype F508DEL/G1244E |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 03.04.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. | ||
| 520 | |a Elexacaftor/tezacaftor/ivacaftor (ETI) is a cystic fibrosis (CF) transmembrane regulator (CFTR) modulator. It is known to be efficacious in stable patients with severe pneumopathy, but there are few data concerning its effectiveness during acute exacerbations. We here describe its use in a woman with CF and respiratory failure | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a genetics | |
| 650 | 4 | |a respiratory medicine | |
| 700 | 1 | |a Colangelo, Carmela |e verfasserin |4 aut | |
| 700 | 1 | |a D'Andria, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Marsicovetere, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Passarella, Domenica |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical case reports |d 2013 |g 9(2021), 8 vom: 31. Aug., Seite e04713 |w (DE-627)NLM234405864 |x 2050-0904 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2021 |g number:8 |g day:31 |g month:08 |g pages:e04713 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ccr3.4713 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2021 |e 8 |b 31 |c 08 |h e04713 | ||